

TACT

Thoracic Alliance for Cancer Trials


Group Leaders' Meeting
WCLC 2015
6th September 2015

Today's discussion

- Current status of TACT
- Membership application process
- Trial proposals

- Tea/coffee break at 9.30 am

> 20 lung cancer and oncology groups represented today



Steering committee

- Paul Mitchell (Chair) ALTG – Australia/NZ
- Glen Goss NCIC-CTG – Canada
- Rebecca Heist Alliance – USA
- Karen Kelly SWOG – USA
- Bartomeu Massuti GECP/SLCG – Spain
- Tony Mok Asia representative; IASLC
- Marianne Nicolson NCRI-CSG – UK
- Mary O'Brien EORTC – Europe
- Ken O'Byrne ALTG – Australia/NZ
- Nick Pavlakis ALTG – Australia/NZ
- Suresh Ramalingam ECOG – USA
- Rolf Stahel ETOP; SAKK – Europe/Switzerland
- Gerard Zalcman IFCT – France

Steering committee priorities

- Establish the structure
- Demonstrate capabilities
- Develop documentation to support governance and operations
- Build awareness and establish relationships

Significant progress since ASCO 2014

- AU\$122k (US\$90k) seed funding
 - Lung Foundation Australia
 - ALTG
 - Industry
- Development Officer recruited
- Dialogue with other multi-national cooperative groups to evaluate different models
 - Gynaecological Cancer Intergroup (GCIG)
 - Breast International Group (BIG)

TACT is formally established today

- Logo under development
- www.TACTlung.com
 - .net and .org will also be linked
- Legal entity – the Lung Foundation Australia
 - Non-profit organisation supporting research, education and advocacy in lung disease
- Mission:
 - An international non-profit umbrella organisation for academic research groups from around the world, dedicated to facilitating thoracic oncology research

Aims

- Facilitate and promote international research collaboration in thoracic cancer
- Provide a platform to conduct clinical trials requiring multiple groups
- Combine resources and expertise to conduct research more efficiently and reduce duplication of effort
- Allow trials to recruit more quickly
- Establish clinical and translational research priorities

Activities

- Develop and conduct trials which require large numbers of patients and/or where accrual is difficult
 - Including multi-modality therapy, rare thoracic malignancies or rare thoracic malignancy subtypes
- Conduct translational research
- Collaborate with other scientific networks
- Develop models of collaboration with the pharmaceutical and biotechnology industry that preserve scientific independence
- Promote other academic thoracic oncology activities

Operating Principles


- Mutual respect and equity for individuals, cultures and nations
- A strong sense of common purpose
- Does not replicate an existing group but provides new opportunities for all its members
- Facilitates and supports the intellectual contributions of individuals and group members and serves as a mechanism to advance these
- All trials remain independent from the pharmaceutical/ biotechnology industry, even if they are sponsored wholly or in part by industry
- All trials follow Good Clinical Practice guidelines and any applicable laws
- There is an agreed set of rules to support fair and efficient processes within the group

2015-2018 is a transition phase

- Twice yearly member meetings at ASCO and WCLC
 - 2016 Chicago, Vienna (Dec)
 - 2017 Chicago, Yokohama (Oct)
 - 2018 Chicago, Toronto (Nov)
- Quarterly Board and Working Group teleconferences
- Move to a fully democratic structure in three years
 - Board members formally voted in by the General Assembly
 - Formally appointed Standing Committees and Working Groups
 - General Assembly will discuss trial proposals

Structure 2015-2018

- Steering committee transitions to Board
- Working groups to be established
- Membership applications open



Full structure in place 2018 (est.)

Board

Standing Committees

Board Executive
& Finance

Nominations

Membership

NSCLC
early

NSCLC
advanced

Small cell, mesothelioma
& rare tumours

Working Groups

Molecular profiling &
translational research

Harmonisation

General Assembly (Member Reps)

First TACT studies

- Large phase III study?
- Randomised phase II trial evaluating sequencing of chemotherapy and PD-1 pathway inhibitor therapy
- Other trials proposed by member groups

Documentation in preparation

- Governance
 - Mission, Aims and Principles
 - Standard Operating Procedures
 - Membership policy
- Trials
 - Intergroup collaboration agreement
 - Publication and authorship policy
 - Indemnity and insurance
 - Quality assurance including safety
 - Data monitoring committee

Awareness and relationships

- Logo and website will be finalised within next two months
 - Raise awareness
 - Group resources
 - Event schedule
 - Contacts
- Dialogue with potential partners during WCLC 2015
 - AbbVie
 - AZ
 - BI
 - BMS
 - Celgene
 - MSD
 - Novartis
 - Roche
 - NCI

Next steps

- Consider submitting a membership application
- Consider involvement in a Working Group
- Submit trial proposals
- All suggestions and feedback welcome

Summary

- We have a unique opportunity to improve the outcomes of patients with thoracic malignancy by facilitating clinical research
- Continue to learn from and adapt the best elements of other collaborative group efforts to date
 - Truly global membership
 - Key governance and operational elements in place from “go”
 - A genuine collaboration among groups and with external partners